Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, announced it will host a virtual investor event on May 28, 2026, at 4:30 p.m. ET. The event will focus on new insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 axis, a key pathway in immune regulation.
The presentation will feature Equillium's management team and scientific advisors, who will discuss the potential of targeting this axis in inflammatory and autoimmune diseases. The company is developing itolizumab, a monoclonal antibody that targets the CD6-ALCAM pathway, which is linked to AhR and miR-124 signaling.
Interested parties can access the live webcast via the Investors section of Equillium's website. A replay will be available for 90 days following the event.
